1-10 of 10
Andreas L Petzer, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3 -ITD: Interim-Analyses of the AMLSG 16-10 Trial

Richard F. Schlenk, MD, Walter Fiedler, MD, Helmut R. Salih, MD, Gerald Wulf, MD, Felicitas Thol, MD, Andrea Kündgen, MD, Thomas Kindler, MD, Hans-Juergen Salwender, MD, Michael Lübbert, MD, Peter Brossart, MD, Jörg Westermann, MD Prof, Doris Kraemer, MD, Katharina Goetze, MD, Heinz-August Horst, MD PhD, Jürgen Krauter, MD, Michael Girschikofsky, MD, Mark Ringhoffer, MD, Thomas Südhoff, MD, Gerhard Held, MD, Hartmut H. Kirchner, MD, Wolff Schmiegel, MD, Richard Greil, MD, Martin Griesshammer, MD, Elisabeth Lange, MD, Uwe Martens, MD, Bernd Hertenstein, MD, Maike de Wit, Elisabeth Koller, MD, Andreas L. Petzer, MD, Tanja Hesse, MD, Volker Runde, MD, Peter Reimer, MD, Beate S. Schultheis, MD, Heinz Kirchen, MD, Frank Griesinger, MD, Holger Hebart, MD, Gerhard Heil, Stephan Kremers, David Nachbaur, MD, Nadezda Basara, MD, Carsten Schwänen, Daniel Schöndube, MD, Jochen Greiner, Anja Münnich, Daniela Weber, Verena I. Gaidzik, MD, Maria-Veronica Teleanu, MD, Peter Paschka, MD, Frauke Theis, Axel Benner, Michael Heuser, MD, Konstanze Döhner, MD, Arnold Ganser, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2016) 128 (22): 449.
https://doi.org/10.1182/blood.V128.22.449.449
Published: 2016
Journal Articles

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Richard Greil, MD, Petra Obrtlikova, MD PhD, Lukas Smolej, MD PhD, Tomas Kozak, MDPhD, Michael Steurer, MD, Johannes Andel, MD, Josef Thaler, MD, Eva Mikuskova, MD, Liana Gercheva, MD, Thomas Nösslinger, MD, Miriam Ladicka, MD, Michael Girschikofsky, MD, MikulᚠHrubiško, MD PhD, Prof., Ulrich Jäger, MD, Michael A. Fridrik, MD, Martin Pecherstorfer, MD, Eva Kralikova, MD, Cristina Burcoveanu, MD, Stefcho Goranov, MD, Jana Jurkovikova, MD, Andreas L. Petzer, MD, Georgi G. Mihaylov, MD PhD, Julian Raynov, MD, Horst Oexle, MD, August Zabernigg, MD, Emilia Flochova, MD PhD, Stanislav Palasthy, MD, Thomas Melchardt, MD, Jiri Mayer, MD, Alexander Egle, MD
Journal: Blood
Blood (2014) 124 (21): 20.
https://doi.org/10.1182/blood.V124.21.20.20
Published: 2014
Journal Articles

Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

Florian Kuchenbauer, MD PhD, Donald W. Bunjes, MD, Wolfgang Herr, MD, Michael Heuser, MD, Daniela Späth, MSc, Jochen Casper, MD, Heinz-August Horst, MD, Peter Brossart, MD, Gerhard Held, MD, Guido Kobbe, MD, Mark Ringhoffer, MD, Mohammed Wattad, MD, Helmut R Salih, MD, Katharina Götze, Gerald Wulf, MD, Matthias Theobald, MD PhD, Mathias J Rummel, MD, Walter Fiedler, MD, Jörg Westermann, MD PhD, Hans Salwender, MD, Andreas L. Petzer, MD, Frank Hartmann, MD, Michael Lübbert, Uwe Martens, MD, Richard Greil, MD, Hartmut H. Kirchner, MD, Peter Paschka, MD, Verena I. Gaidzik, MD, Veronica Teleanu, MD, Felicitas Thol, MD, Gudrun Göhring, PD, Konstanze Döhner, MD, Arnold Ganser, Hartmut Döhner, MD, Richard F. Schlenk, MD
Journal: Blood
Blood (2014) 124 (21): 1254.
https://doi.org/10.1182/blood.V124.21.1254.1254
Published: 2014
Journal Articles

A Phase I Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukaemia (CMML) – AGMT_CMML 1

Sonja Burgstaller, MD, Richard Greil, MD, Reinhard Stauder, MD MSc, Sigrid Machherndl-Spandl, MD, Michael Pfeilstöcker, MD, Thomas Kuehr, MD, Alois Lang, MD, Beate Mayrbaeurl, MD, Andreas L. Petzer, MD, Peter Valent, MD, Josef Thaler, MD
Journal: Blood
Blood (2014) 124 (21): 3268.
https://doi.org/10.1182/blood.V124.21.3268.3268
Published: 2014
Journal Articles

Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

Richard F. Schlenk, MD, Konstanze Döhner, MD, Michael Heuser, MD, Daniela Späth, MSc, Carina Morlok, Alexander Lamparter, Klaus-Henning Koehne, M.D., Heinz-August Horst, MD, Peter Brossart, MD, Gerhard Held, Andrea Kündgen, M.D., Mark Ringhoffer, MD, Mohammed Wattad, MD, Helmut R. Salih, MD, Katharina S. Goetze, MD, Gerald Wulf, MD, Matthias Theobald, MD, PhD, Mathias J. Rummel, MD, Walter Fiedler, MD, Jörg Westermann, MD, Hans Salwender, MD, Andreas L. Petzer, MD, Frank Hartmann, MD, Michael Lübbert, MD, Uwe M. Martens, MD, Richard Greil, MD, Hartmut Kirchner, MD, Peter Paschka, MD, Verena I. Gaidzik, MD, Sabine Kayser, MD, Veronica Teleanu, MD, Felicitas Thol, MD, Gudrun Göhring, MD, Arnold Ganser, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2013) 122 (21): 3878.
https://doi.org/10.1182/blood.V122.21.3878.3878
Published: 2013
Journal Articles

Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3 -ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial

Sabine Kayser, MD, Mark Levis, MD, PhD, Carina Morlok, Andrea Kuendgen, MD, Michael Heuser, MD, Walter Fiedler, MD, Joerg Westermann, MD, Katharina Goetze, MD, Helmut R. Salih, MD, Andreas L. Petzer, MD, Frank Hartmann, MD, Heinz A. Horst, MD, Uwe M. Martens, MD, Gerald Wulf, MD, Michael Luebbert, MD, Ph.D., Dominik Wolf, MD, Richard Greil, MD, Claus-Henning Koehne, MD, Mark Ringhoffer, MD, Hartmut Kirchner, MD, Michael Pfreundschuh, MD, Brigitte Schlegelberger, MD, PhD, Patricia Erdmann, Trivikram Rajkhowa, Peter Paschka, MD, Verena I. Gaidzik, MD, Veronica Teleanu, MD, Felicitas Thol, MD, Arnold Ganser, Hartmut Doehner, MD, Konstanze Doehner, MD, Richard F. Schlenk, MD
Journal: Blood
Blood (2013) 122 (21): 1283.
https://doi.org/10.1182/blood.V122.21.1283.1283
Published: 2013
Journal Articles

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Michael Fridrik, MD, Andreas L Petzer, MD, Felix Keil, MD, Wolfgang Willenbacher, MD, Ulrich Jäger, MD, Alois Lang, MD, Johannes Andel, MD, Otto Krieger, MD, Wilhelm Oberaigner, Richard Greil, MD
Journal: Blood
Blood (2010) 116 (21): 1766.
https://doi.org/10.1182/blood.V116.21.1766.1766
Published: 2010
Journal Articles

Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study

Alexander Egle, MD, Lukas Weiss, Franz Gassner, Gudrun Russ, Lisa Pleyer, Eberhard Gunsilius, MD, Inge Tinhofer, Josef Thaler, MD, Andreas L. Petzer, MD, Richard Greil
Journal: Blood
Blood (2008) 112 (11): 3175.
https://doi.org/10.1182/blood.V112.11.3175.3175
Published: 2008
Journal Articles

CELSG CML 11 “ISTAHIT” Phase III Study – Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph + /BCR-ABL + CML Patients in Chronic Phase.

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominic Fong, MD, Thomas Lion, MD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Stefan Goranov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Radka Oucheva, MD, Hanno Ulmer, PhD, Marthin Kwakkelstein, MD, Gianluca Fincato, MD, Guenther Gastl, MD
Journal: Blood
Blood (2008) 112 (11): 1112.
https://doi.org/10.1182/blood.V112.11.1112.1112
Published: 2008
Journal Articles

Multicenter, Randomized, Phase III Study Comparing Imatinib (Glivec) Standard Dose (400 mg/d) with Imatinib High Dose Induction (800 mg/d) Followed by Imatinib Maintenance (400 mg/d) in Patients with Pretreated Ph + /BCR-ABL + CML in Chronic Phase - Results from the First Planned Interim Analysis (CELSG-CML 11 ISTAHIT Study).

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominik Fong, MD, Thomas Lion, MD, PhD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Emil Spasov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Atanas Stanchev, MD, Martin Kwakkelstein, MD, Hanno Ulmer, PhD, Guenther A. Gastl, MD
Journal: Blood
Blood (2007) 110 (11): 1048.
https://doi.org/10.1182/blood.V110.11.1048.1048
Published: 2007